Kazia Therapeutics (KZIA) EBIT (2009 - 2011)

Kazia Therapeutics has reported EBIT for 3 years, with the latest figure at -$950387.2 in Q4 2011.

• For the quarter ending Q4 2011, EBIT rose 81.61% year-over-year to -$950387.2; the trailing twelve-month figure through Dec 2011 stood at -$17.4 million (up 38.08% YoY), and the FY2025 full-year result was -$14.4 million, up 19.35% from the prior year.
• EBIT for Q4 2011 stood at -$950387.2, up from -$5.2 million in the prior quarter.
• The five-year high for EBIT was -$950387.2 in Q4 2011, with the low at -$5.8 million in Q4 2009.
• Historically, EBIT has averaged -$4.0 million across 3 years, with a median of -$5.2 million in 2010.
• Annual changes were most pronounced in 2010 — EBIT gained 11.24% — and 2011, when it soared 81.61%.
• Kazia Therapeutics' EBIT stood at -$5.8 million in 2009, then rose by 11.24% to -$5.2 million in 2010, then soared by 81.61% to -$950387.2 in 2011.
• The last three EBIT figures came in at -$950387.2 (Q4 2011), -$5.2 million (Q4 2010), and -$5.8 million (Q4 2009), per Business Quant data.